Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | $115.39K | $6.55M |
| Cost of Revenue | N/A | $5.87M | N/A | N/A | N/A | $17.22K | $4.25M |
| Gross Profit | N/A | $-5.87M | N/A | N/A | N/A | $98.17K | $2.30M |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 85.08% | 35.08% |
| Operating Expenses | $128.19M | $125.78M | $118.95M | $86.43M | $51.51M | $22.45M | $2.65M |
| Operating Income | $-128.19M | $-131.65M | $-118.95M | $-86.43M | $-51.51M | $-22.35M | $-356.45K |
| Operating Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -19368.66% | -5.44% |
| Net Income | $-108.79M | $-117.50M | $-113.84M | $-86.08M | $-91.36M | $-21.08M | $-274.50K |
| Net Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -18265.66% | -4.19% |
| EPS (Basic) | $-1.60 | $-2.40 | $-2.61 | $-2.62 | $-1.59 | $-2.55 | $-0.01 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A |